Zobrazeno 1 - 10
of 1 338
pro vyhledávání: '"t-dm1"'
Autor:
Elena Giordani, Matteo Allegretti, Alberto Sinibaldi, Francesco Michelotti, Gianluigi Ferretti, Elena Ricciardi, Giovanna Ziccheddu, Fabio Valenti, Simona Di Martino, Cristiana Ercolani, Diana Giannarelli, Grazia Arpino, Stefania Gori, Claudia Omarini, Alberto Zambelli, Emilio Bria, Ida Paris, Simonetta Buglioni, Patrizio Giacomini, Alessandra Fabi
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-11 (2024)
Abstract Background During targeted treatment, HER2-positive breast cancers invariably lose HER2 DNA amplification. In contrast, and interestingly, HER2 proteins may be either lost or gained. To longitudinally and systematically appreciate complex/di
Externí odkaz:
https://doaj.org/article/92bb4cafdd7145c5a75ef4fcaf8a3e78
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/7d013f6d4a1f4a17a4770467fbbfcbad
Autor:
Ciara C. O’Sullivan, Alexandra S. Higgins, Adham K. Alkurashi, Vaibhav Ahluwalia, Jodi L. Taraba, Paul M. McKie, Patrick S. Kamath, Vivek N. Iyer, Tufia C. Haddad
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe advent of antibody-drug conjugates (ADCs) represents a landmark advance in cancer therapy, permitting targeted delivery of a potent cytotoxic agent to tumor cells with minimal damage to surrounding cells. Although ADCs can induce sustai
Externí odkaz:
https://doaj.org/article/17cffb39203f42398b030ad1b66626b6
Autor:
Fateme Yazdani, Negar Mottaghi-Dastjerdi, Behzad Shahbazi, Khadijeh Ahmadi, Abozar Ghorbani, Mohammad Soltany-Rezaee-Rad, Hamed Montazeri, Farzane Khoshdel, Pietro Hiram Guzzi
Publikováno v:
Heliyon, Vol 10, Iss 18, Pp e37451- (2024)
Introduction: Esophageal Cancer (EC) ranks among the most common malignancies worldwide. Most EC patients acquire drug resistance to chemotherapy either intrinsically or acquired after T-DM1 treatment, which shows that increasing or decreasing the ex
Externí odkaz:
https://doaj.org/article/d215ae60545a489d91b29722cabbf741
Publikováno v:
Journal of Applied Pharmaceutical Research, Vol 12, Iss 2, Pp 35-41 (2024)
Background: HER2 (Human Epidermal Growth Receptor 2) positive breast cancer is an aggressive subtype. Treatment for patients with HER2-positive breast cancer has advanced significantly over time with the introduction of targeted therapies like trastu
Externí odkaz:
https://doaj.org/article/a2d77bc134ee47dbb386d055a729cebc
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more dura
Externí odkaz:
https://doaj.org/article/c30874be81f04b78be67858f937fdb82
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundBreast cancer (BC) is one of the most common cancers worldwide. The inevitability of drug resistance to initial anti-HER-2 therapy necessitates the emergence of second-line anti-HER-2 drugs which exhibit a promising outlook. Consequently, i
Externí odkaz:
https://doaj.org/article/762dd4d5e51044a19e4be0c7e8706e3c
Autor:
Miao He, Wen Zhao, Peng Wang, Wenhuan Li, Hanhan Chen, Zonghuai Yuan, Guangye Pan, Hong Gao, Lijun Sun, Jiahui Chu, Li Li, Yu Hu
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundTrastuzumab emtansine (T-DM1) has been approved worldwide for treating metastatic breast cancer (mBC) in patients who have received first-line therapy, shown disease progression, and are human epidermal growth factor receptor 2 (HER2)-posit
Externí odkaz:
https://doaj.org/article/bec0fea95b7f460cb18ae71082b01be4